 |
Top 5 Dementia startups
Updated: April 15, 2024 | Editor: Jason Kwon |
These startups develop new Dementia management and treatment technologies, like AI-powered imaging and drug-discovery, gene therapy, stem cells, virtual reality systems for the cognitive neurorehabilitation.
1
Country: USA | Funding: $135.5M
QurAlis is specifically focused on discovering & developing new therapies for amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease.
QurAlis is specifically focused on discovering & developing new therapies for amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease.
2
Country: USA | Funding: $71.3M
SafelyYou is the artificial intelligence-enabled fall detection and prevention for dementia care.
SafelyYou is the artificial intelligence-enabled fall detection and prevention for dementia care.
3
Country: Germany | Funding: $6.7M
Lindera has developed the 1st quantitative mobility self-test for seniors by analyzing the gait to prevent falls.
Lindera has developed the 1st quantitative mobility self-test for seniors by analyzing the gait to prevent falls.
4
Country: Sweden | Funding: SEK15M
Geras Solutions aims to provide a clear pathway towards a reliable dementia specialist that is time and cost-effective. The Geras Solutions App offers individuals living with dementia and carers an ecosystem of digital dementia supportive solutions via an easy to use mobile health tool.
Geras Solutions aims to provide a clear pathway towards a reliable dementia specialist that is time and cost-effective. The Geras Solutions App offers individuals living with dementia and carers an ecosystem of digital dementia supportive solutions via an easy to use mobile health tool.
5
Country: Germany
Priavoid envisions curing neurological disorders by developing innovative treatment strategies based on a new class of orally available compounds. Focusing on indications with significant unmet medical need Priavoid applies the therapeutic concept to Alzheimer’s disease (AD), neuropathic pain and other neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), tauopathies, Parkinson’s disease (PD), and Huntington’s disease (HD).
Priavoid envisions curing neurological disorders by developing innovative treatment strategies based on a new class of orally available compounds. Focusing on indications with significant unmet medical need Priavoid applies the therapeutic concept to Alzheimer’s disease (AD), neuropathic pain and other neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), tauopathies, Parkinson’s disease (PD), and Huntington’s disease (HD).
